Related resources
Full-text held externally
- PMID: 24262145
- UKPMCID: 24262145
- DOI: 10.1136/jmedgenet-2013-102038
Search for item elsewhere
University researcher(s)
Academic department(s)
A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1.
Livingston, John H; Lin, Jean-Pierre; Dale, Russell C; Gill, Deepak; Brogan, Paul; Munnich, Arnold; Kurian, Manju A; Gonzalez-Martinez, Victoria; De Goede, Christian G E L; Falconer, Alastair; Forte, Gabriella; Jenkinson, Emma M; Kasher, Paul R; Szynkiewicz, Marcin; Rice, Gillian I; Crow, Yanick J
Journal of medical genetics. 2014;51(2):76-82.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 24262145
- UKPMCID: 24262145
- DOI: 10.1136/jmedgenet-2013-102038
Abstract
BACKGROUND: We recently observed mutations in ADAR1 to cause a phenotype of bilateral striatal necrosis (BSN) in a child with the type I interferonopathy Aicardi-Goutières syndrome (AGS). We therefore decided to screen patients with apparently non-syndromic BSN for ADAR1 mutations, and for an upregulation of interferon-stimulated genes (ISGs). METHODS: We performed Sanger sequencing of ADAR1 in a series of patients with BSN presenting to us during our routine clinical practice. We then undertook detailed clinical and neuroradiological phenotyping in nine mutation-positive children. We also measured the expression of ISGs in peripheral blood from these patients, and in children with BSN who did not have ADAR1 mutations. RESULTS: Nine ADAR1 mutation-positive patients from seven families demonstrated an acute (five cases) or subacute (four cases) onset of refractory, four-limb dystonia starting between 8 months and 5 years of age. Eight patients were developmentally normal at initial presentation. In seven cases, the disease was inherited as an autosomal recessive trait, while two related patients were found to have a heterozygous (dominant) ADAR1 mutation. All seven mutation-positive patients assayed showed an upregulation of ISGs (median: 12.50, IQR: 6.43-36.36) compared to controls (median: 0.93, IQR: 0.57-1.30), a so-called interferon signature, present many years after disease onset. No interferon signature was present in four children with BSN negative for mutations in ADAR1 (median: 0.63, IQR: 0.47-1.10). CONCLUSIONS: ADAR1-related disease should be considered in the differential diagnosis of apparently non-syndromic BSN with severe dystonia of varying evolution. The finding of an interferon signature provides a useful screening test for the presence of ADAR1 mutations in this context, and may suggest novel treatment approaches.